On June 4, 2010, the first stone was officially laid for what will most certainly become a centre of excellence in biotechnological development and research, providing treatments for serious diseases.

This investment confirms our intent to anchor our research in Belgium and the construction of the plant is part of the process of transforming UCB into a biopharmaceutical company, focusing on serious illnesses of the central nervous system and on immunological problems.